![](/rp/kFAqShRrnkQMbH6NYLBYoJ3lq9s.png)
Facet Hypertrophy | Diagnosis & Disease Information
Sep 12, 2022 · Etiology and Risk Factors. Spondylosis, or degeneration of the spine, is the most common cause of facet joint disease. Osteoarthritis, or degeneration that is due to natural wear and tear, is a process that involves cytokines and proteolytic enzymes. Other causes of facet hypertrophy can include trauma caused by car accidents, sports injuries, or falls. 1
2022 ACR/AAHKS Guidelines for Management of
Apr 6, 2022 · References. American College of Rheumatology & American Association of Hip and Knee Surgeons. 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty: guideline summary.
FDA Roundup: Rheumatology Drug Alerts 2024
Mar 5, 2024 · Throughout 2024, the United States Food and Drug Administration (FDA) approved new drugs for the treatment of osteoporosis, rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), giant cell arteritis, Duchenne muscular dystrophy (DMD), and certain cancers, while also expanding treatment indications for previously approved drugs.
Hydroxyapatite Crystal Deposition Disease (HADD)
Nov 15, 2022 · History and Epidemiology. A typically uniarticular condition, hydroxyapatite (HA) crystal deposition disease (HADD) is marked by the presence of hydroxyapatite crystals in the periarticular soft tissues, especially the tendons 1.HA is a mineral found in normal bone, but when it builds up in and around the joints it can cause inflammation, tenderness, and pain.
Undifferentiated Connective Tissue Disease - Rheumatology Advisor
Aug 9, 2022 · Undifferentiated connective tissue disease (UCTD) is a diagnosis of exclusion. Patients who present with clinical and serolotical manifestations that suggest a systemic autoimmune disease but do not fulfill criteria for defined connective tissue disease (eg, systemic lupus erythematosus, scleroderma, myositis, rheumatoid arthritis, Sjogren's syndrome) are classified to have UCTD.
American College of Rheumatology Releases Updated Guidelines …
Jun 18, 2021 · The American College of Rheumatology (ACR) recently released updated guidelines for the pharmacologic management of rheumatoid arthritis (RA). The full report has been published simultaneously in Arthritis Care & Research and Arthritis & Rheumatology.. Overall, the updated guidelines include treatment with disease-modifying antirheumatic drugs (DMARDs), including biologic DMARDs (bDMARDs) and ...
Choosing the Right TNF Inhibitor Therapy for Rheumatoid Arthritis
Dec 20, 2017 · Biologics, approved nearly 20 years ago for the treatment of rheumatoid arthritis (RA), transformed treatment, and tumor necrosis factor inhibitors (TNFis) are now usually the first and most frequently used biologics. 1. Although all TNFis block TNFα and are broadly similar in efficacy and toxicity, resulting in little preference of one over another, there are important differences in TNFis ...
Rare and Unusual Clinical Presentations of Gout
Apr 19, 2024 · Gout is a type of inflammatory arthritis characterized by the deposition of monosodium urate crystals and the formation of tophi in tissues, typically in or around the joints. 1 Gout occurs more commonly in men compared with women 2 and “usually presents with sudden onset of severe pain, redness, and swelling of a single joint, most often in the feet, ankle, or knee,” said Rebecca ...
Bimekizumab May Reduce Risk for Uveitis in Axial Spondyloarthritis
Oct 23, 2024 · For patients with axial spondyloarthritis (axSpA) who experience extra musculoskeletal symptoms such as acute anterior uveitis, bimekizumab (BKZ) may offer protective benefits, according to study results published in Annals of the Rheumatic Diseases.. Researchers conducted a pooled analysis of data from the following phase 2b/3 trials: BE MOBILE 1 (ClinicalTrials.gov Identifier: NCT03928704 ...
Updated 2019 ACR Recommendations for Treatment of …
Sep 9, 2019 · Based on new evidence and an expert consensus, the American College of Rheumatology (ACR), the Spondylitis Association of America, and the Spondyloarthritis Research and Treatment Network released updated recommendations for the treatment of axial spondyloarthritis (SpA), which comprises ankylosing spondylitis (AS) and …